Navigation Links
Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
Date:2/20/2008

SOUTH SAN FRANCISCO, Calif., Feb. 20 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it has earned a preclinical milestone payment from Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) under the companies' drug discovery collaboration agreement.

The two companies entered into a research collaboration in May 2002 to discover oral small molecule enzyme inhibitors for the treatment of major chronic inflammatory and autoimmune diseases. The recent milestone payment was triggered by J&JPRD's selection of a compound targeting the Cathepsin S enzyme as a development candidate. Under the terms of the collaboration agreement, Sunesis has the potential to receive additional development milestone payments from J&JPRD, as well as royalty payments based on future product sales.

"We believe that a small molecule inhibitor of Cathepsin S will provide a useful approach to treating certain inflammatory conditions and we are pleased by J&JPRD's advancement of a compound from our collaboration into development," said Bob McDowell, Ph.D., Vice President of Research at Sunesis.

About Cathepsin S

Cathepsin S is an enzyme involved in the activation of immune system T-cells. Inhibiting inappropriate activation of T-cells may lead to novel treatments of certain inflammatory and autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
2. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
4. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
5. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
6. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
7. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
8. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
9. Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA Seal Of Approval
10. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results
11. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)... , Fuel economy ratings for the new 2010 model y...nomy.gov web site, which Oak Ridge National Labor...ent of Energy and the U.S. Environmental Protectio...fuel economy list are hybrid electrics, led by the...t proves that hybrids have gone mainstream," said ...
(Date:11/5/2009)...wswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: ... for processing and storing adult stem cells, toda... 2010. ,, For the quarter ended September 30, 2..., a 15 percent increase over revenues of $4.5 mill...aid the key contributors to the growth in revenues...
(Date:11/5/2009)...e-FirstCall/ -- Wound Management Technologies, Inc...o a Letter of Intent to purchase all healthcare-re...(OTC Bulletin Board: VHGI). The deal provides for ...,000 shares of WNDM and a royalty agreement for re...gy being acquired from VHGI. WNDM closed at $2.0...
(Date:11/5/2009)...ialty firm BioSoteria announced that its Vice Pres...ified Professional in Learning and Performance&tra...r Training and Development (ASTD) Certification In...ears of medical communications and health care tra...pment of the company,s online pharmacovigilance cu...
Breaking Biology Technology:November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 2November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 2OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 3BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification 2BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification 3BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification 4
...RNewswire-FirstCall/ - AEterna Zentaris Inc.,(TSX:...mpany focused on,endocrine therapy and oncology, t...eting the management team with the appointment of ...f Medical Officer. "The appointment of Dr. Blake ... to bring our flagship product candidate, cetrorel...
...ugust 16 Healthcare,Technologies Ltd. (NASDAQ: H...xtraordinary general meeting of its shareholders t...the offices of Yigal Arnon & Co., 1 Azrieli,Center...he meeting, shareholders will be asked to approve ...with NexGen Biofuels, Inc, Mac,Bioventures Inc. an...
...p Supported by Multi-Year $1.3 Million Grant to th...LADELPHIA, Aug. 16 Daniel F. Hayes, MD, a Univers...hose work in clinical and,laboratory studies has a...was named today as the first winner of the annual ... a multi-year grant of more than $1.3 million,from...
Other Biology Technology:AEterna Zentaris completes management team with the appointment of Chief Medical Officer 2AEterna Zentaris completes management team with the appointment of Chief Medical Officer 3Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction 2Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction 3GlaxoSmithKline Recognizes University of Michigan's Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award 2GlaxoSmithKline Recognizes University of Michigan's Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award 3
(Date:11/3/2009)...rom the UCLA Henry Samueli School of Engineering a...fully reconstituted in the laboratory the enzyme r...ol-lowering drug lovastatin. , The research, ...potentially lead to the development of other compo... lovastatin-synthesizing enzyme is one of the most...
(Date:11/3/2009)...t the University of Illinois at Chicago have recei...lood Institute to study the relationship between "...obesity. , The funding for the two-year project ...nd Reinvestment Act of 2009. , The study will li... with specific sugar- and fat-laden foods and beve...
(Date:11/3/2009)...ISCO, Nov. 3 EmSense Corporation, ...logical and brainwave measurement technology, toda...C round of funding, led by an investment from Tech... Group also participating. ,, This funding will... support of its many market research partners. Th...
Breaking Biology News(10 mins):UCLA researchers reconstitute enzyme that synthesizes cholesterol drug lovastatin 2UIC receives $1 million grant to study 'fat taxes,' diet, obesity 2EmSense Raises $9 Million Series C Round of Financing 2Department of Aging Urges Citizens to Report Abuse and Neglect of Older Adults 52784 1Department of Aging Urges Citizens to Report Abuse and Neglect of Older Adults 52784 2Independence Blue Cross Harnesses Technology to Connect the Dots on Patient Care 52780 1Independence Blue Cross Harnesses Technology to Connect the Dots on Patient Care 52780 2Independence Blue Cross Harnesses Technology to Connect the Dots on Patient Care 52780 3Independence Blue Cross Harnesses Technology to Connect the Dots on Patient Care 52780 4Olympus Managed Health Care Receives Third Party Administrative License in State of Florida 52776 1
...essor of Chemical Engineering and Director of the ...tute of Technology, has won the Society of Plastic...n C. Moricoli)., Kalyon received his B.Eng. in Che...g. and Ph.D. in Chemical Engineering/Polymers at M... primary accomplishment has been the generation of...
...ist Darla Goeres knows that there is more than one...ke sure that when a product claims it kills "99 pe...ofilms are the extremely common communities of bac...rom the plaque on teeth to the slime on streamside...ofilms are harmless, but some have been linked to ...
...access 3D images of biomacromolecules underlying b...ng on text to provide the understanding of biomacr...ed Proteopedia now provides a new resource by link...ctural information. The wiki web resource, first d...enome Biology, displays protein structures and oth...
Other Biology News:MSU biofilms research helps set standards for everyday products 2
Guanosine 5′-O-(2-Thiodiphosphate), Trilithium Salt from Calbiochem
G(5)ppp(5)G from Ambion
Boekel Rocker II 115VAC from Boekel Scientific
Microtiter Wells from Bethyl Laboratories
Biology Products: